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the integrated care of asthma in many areas. One way
to address this is through greater involvement of
patients in their own management. Asthma action
plans have been shown to work when these plans are
personalised and imaginatively linked to the individual
patient’s goals and problems. The guidelines provide
an excellent resource and should act as a stimulus for
patients and staff to work together to provide
appropriate care in asthma.
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Safety and efficacy of interventional procedures
Scrutinising the evidence and issuing guidelines without stifling innovation
Throughout the world, systems are in place toensure that any new drug is subjected to rigor›ous trials, appraisal, and approval before unre›
stricted use on patients. Medical devices are also
subject to scrutiny and approval. By contrast no system
exists for interventional procedures, many of which are
done by surgeons but increasingly by other specialists
as well. Recent press reports of surgical scandals and
heightened public concern have led to political and
consumer pressure for formal systems to assess new
interventions.
In the United Kingdom, initial moves were made in
1996 by the setting up of the Safety and Efficacy Regis›
ter for New Interventional Procedures (SERNIP). It was
founded by the royal colleges, with limited funding
from the NHS, and was entirely voluntary. The register
gradually accumulated a list of new procedures and
allocated each to a category signifying its perceived
degree of safety and efficacy, but the profile and impact
of this register were limited. Australia followed suit with
the Australian Safety and Efficacy Register for New
Interventional Procedures—Surgical (ASERNIP›S)—
established by the Royal Australasian College of
Surgeons and funded by the Commonwealth Depart›
ment of Health and Ageing—and made more tangible
progress.1
The Australian surgery register has published
systematic reviews on a range of surgical procedures,2
with recommendations about their use or the need for
further evaluation. Funding has limited the register to
reviewing a maximum of about 10 procedures each
year, ranging from laparoscopic live›donor nephrec›
tomy3 to ultrasound assisted liposuction.4 Hospitals in
Australia have generally acted on advice from the reg›
ister, promoting the use of procedures along
recommended lines and restricting the use of others
pending more evidence. Recommendations from the
register have provided increased impetus for system›
atic audit of some procedures and have stimulated a
randomised trial of laparoscopic colonic surgery.5 It
has also established a horizon scanning project with a
database of procedures, either recently introduced or
likely to find their way into surgical practice soon,6
which can be systematically reviewed when sufficient
evidence exists.
In the United Kingdom, one result of the Bristol
affair was a mandate for the National Institute for
Clinical Excellence (NICE, www.nice.org.uk) to take
over responsibility for safety and efficacy of interven›
tional procedures, with a remit altogether more
comprehensive and demanding than that of its
predecessor or of the Australian surgery register.7
Expectations include a database of all new procedures,
cooperation of all surgeons and other doctors
undertaking new procedures, and recommendations
that will be observed throughout the health service—all
in a process that is public and transparent. Success,
therefore, requires a balance between the primary aim
of protecting patients and the need to encourage and
foster innovation. Doctors will need to be engaged by
clear assurances that their own protection from clinical
and medicolegal risk is a central theme.
The intention is to review the evidence about new
procedures, and to collect data on all cases for
procedures under special scrutiny—rather than
attempting to restrict their use. This will be a complex
exercise but has the potential to gather information
about safety and efficacy quickly. The Australian
surgery register has experienced the difficulties of data
collection by using a range of data submission
techniques ranging from paper through to fax and web
based systems. NICE is committed to electronic data
capture, with much smaller datasets, including only key
items about safety and efficacy. The coordinated system
of clinical governance now established in the United
Kingdom is likely to facilitate this.8 Protecting private
patients is more difficult, but involving the private
sector seems important because this is where many
new procedureare first undertaken.
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Collection and validation of data on a large scale
are expensive, and the cost of systematic reviews
is considerable—an average of £30 000›£50 000
($48 800›$81 350; &45 500›&75 800) for the Australian
register. Funding is unlikely ever to be sufficient for
collection of data on all procedures, and NICE will rely
heavily on help from a network of specialist advisers
and on its multidisciplinary advisory committee.
No other countries yet have systems in place for
monitoring of new interventions. The American
College of Surgeons is considering an approach but
has yet to act. The Australian example and the more
regulated United Kingdom plan may give other coun›
tries food for thought, but many uncertainties remain.
What precisely is a new procedure? If an existing pro›
cedure is modified, how much modification makes it
new? If new technology is used for an established pro›
cedure, is that new? (NICE will be explicit about its
focus on procedures rather than devices.) Should doc›
tors be restricted in undertaking new procedures? How
can compliance with submission of data and guidance
best be achieved? What data should be publicly
available and what should be done if outcomes vary
between doctors? Without clear assurances about
confidentiality neither doctors nor patients will be
eager to cooperate.
Finally, safety and efficacy also require a long term
perspective. NICE intends to ensure that new
procedures receive specific codes in the national
coding system at an early stage, so that their dissemina›
tion can be monitored and any reporting of adverse
events is in the context of some kind of denominator.
Procedures with obvious potential for long term
adverse events will need special consideration, and this
will form part of the complex evolution of monitoring
of safety and efficacy.
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Not to be taken as directed
Putting concordance for taking medicines into practice
When the medicines that doctors prescribefail to produce the benefit they expect, theyoften respond by varying the dose or select›
ing an alternative medicine. Thus doctors seem to
behave as though non›compliance is a problem for
other doctors. Although we know that about half of the
medicines prescribed for patients with long term con›
ditions are not taken as prescribed,1 the concerns of
health professionals have focused almost exclusively
on improving the quality of their own prescribing
choices. Similarly, attention and resources devoted by
pharmaceutical companies to discovering, developing,
and promoting new drugs utterly dwarf their efforts to
see that medicines are taken by patients. Yet
non›compliance continues to represent a serious
therapeutic deficit at the core of medical practice, with
consequent massive personal, societal, and economic
cost.
Patients do not comply with medication for several
reasons.2 Non›compliance may be intentional or invol›
untary. It may relate to the quality of information given,
the impact of the regimen on daily life, the physical or
ental incapacity of patients, or their social isolation.
Many interventions to overcome these impediments
have been tried, but evidence of sustained success is
scant.1
The difficulty for health professionals lies in
acknowledging that it is the patients’ agendas and not
their own that determine whether patients take
medicines. Patients have their own beliefs about their
medicines and medicines in general. They have their
own priorities and their own rational discourse in rela›
tion to health and care, risk and benefit.3 These may
differ from and sometimes contradict those of the doc›
tors. They are, however, no less cogent, coherent, or
important.4
By drawing on these findings and insights a new
relationship between prescriber and patient was
described.5 The term concordance was introduced.
While compliance describes the degree to which the
patient follows the prescribed regimen of medicines,
concordance describes an agreement between a
patient and a healthcare professional about whether,
when, and how medicines are to be taken. Concord›
ance therefore refers to the creation of an agreement
that respects the beliefs and wishes of the patient, and
not to compliance—the following of instructions.
Doctors and patients may not always agree. The
implication of concordance is that when this happens
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